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The accumulation of transition metals (e.g., copper, zinc, and iron) and the dysregulation of their metabolism are a hallmark in
the pathogenesis of several neurodegenerative diseases. This paper will be focused on the mechanism of neurotoxicity mediated
by iron. This metal progressively accumulates in the brain both during normal aging and neurodegenerative processes. High
iron concentrations in the brain have been consistently observed in Alzheimer’s (AD) and Parkinson’s (PD) diseases. In this
connection, metalloneurobiology has become extremely important in establishing the role of iron in the onset and progression
of neurodegenerative diseases. Neurons have developed several protective mechanisms against oxidative stress, among them, the
activation of cellular signaling pathways. The ﬁnal response will depend on the identity, intensity, and persistence of the oxidative
insult. The characterization of the mechanisms mediating the eﬀects of iron-induced increase in neuronal dysfunction and death
is central to understanding the pathology of a number of neurodegenerative disorders.
1.Introduction
The so-called “biometals” (e.g., iron, copper, or zinc) are
known to play a fundamental role in numerous essential
metabolic processes, thus being considered as essential for
life. Metal ion homeostasis is maintained through highly
regulated mechanisms of uptake, storage, and secretion [1].
A speciﬁc set of transporters functions in each cellular com-
partment to provide a strict balance of transport activities
across their membranes. Nonbound copper and iron are
potentially harmful mainly due to their redox activities.
Normally, under healthy conditions, these metal ions are
bound to ligands (e.g., transferrin, ceruloplasmin), and they
a r en o tf o u n da sf r e es p e c i e s .H o w e v e r ,t h er e l e a s eo ff r e e
ionic or exchangeable zinc and copper has been reported in
the synaptic cleft. In addition, zinc is also being increasingly
involved in several cellular reactions like calcium, and it has
been proposed as a new class of second messenger.
A loss or an abnormal metal homeostasis might cause
cellular death or severe dysfunction, and it has been recog-
nized as a triggering factor for diﬀerent neurodegenerative
disorders such as Alzheimer’s (AD), Parkinson’s (PD), and
Huntington’s (HD) diseases as well as amyotrophic lateral
sclerosis (ALS) [2–6]. Although the etiology of these diseases
is still largely unknown, oxidative damage mediated by
metals has been thought to be a signiﬁcant contributor
since metals such as iron, aluminum, zinc, and copper have
been observed to be dysregulated and/or increased in AD
brains and prone to generate a pro-oxidative environment
[7–11].Takingintoaccountthegreatamountofinformation
regarding the role of transition metals in cell biology,
this paper will be mainly focused on the role of iron in
neurodegeneration.
Loss of iron may cause neurological disease, and, in
opposition, its accumulation or abnormal interaction with
cellular components such as proteins, lipids, or nucleic acids
may also contribute to neurodegenerative disorders. The
intracellular pool of free iron, the labile iron pool (LIP), has
been well established to modulate the expression of various
proteins, including the amyloid precursor protein (APP)
[12, 13].
In the brain, the movement of metals across the blood-
brain barrier is highly regulated, and there is no passive
ﬂux of metals from the circulation to the brain [1, 14].2 International Journal of Alzheimer’s Disease
While iron, copper, and zinc are being increasingly impli-
cated in interactions with the major protein components
of neurodegenerative diseases, this is not merely due to
increased (e.g., toxicological) exposure to metals but rather
because of a breakdown in the homeostatic mechanisms that
compartmentalize and regulate metals [7].
The ability of iron to accept and donate electrons can
lead to the formation of reactive nitrogen and oxygen species
(thelatter named “ROS” in this paper) which may trigger the
oxidativeattackoftissuecomponents,thereforecontributing
to disease and perhaps aging itself [15, 16]. Increasing age
is the main risk factor associated with the appearance of
neurodegenerative diseases. Several studies in animals and
humans have reported a rise in brain iron as a function of
ageing [17, 18]. The vulnerability of the brain to abnormal
iron regulation has been demonstrated by the relationship
between the failure of ferroxidases, ceruloplasmin [19, 20],
ferritin [18, 21, 22], and frataxin [23, 24], iron accumulation
(IA), and the onset of neurodegenerative diseases.
2. Iron Accumulation in
Neurodegenerative Diseases
The accumulation of transition metals in the nervous system
is a common observation in diﬀerent neurodegenerative
diseases that support a role of metals in these disorders
[25, 26]. Particularly, iron homeostasis has shown to be
altered [26, 27]. Excessive iron deposition has been reported
to occur in the central nervous system (CNS) in a number
of neurodegenerative pathologies such as AD, PD, ALS, and
neuroferritinopathies, among others [4, 28–33].
ALS is a neurodegenerative disorder characterized by
progressive paralysis of skeletal muscles and degeneration of
motor neurons in the spinal cord, brainstem, and cortex.
High levels of iron in the CNS of both familial and sporadic
forms of ALS have been reported [32, 34, 35]. However,
neither the mechanisms underlying iron accumulation nor
its complete role in the pathogenesis of the disease are clear.
Neuroferritinopathies, like neurodegeneration with
brainironaccumulation(NBIA),aredeﬁnedasextrapyrami-
dal disorders [33] characterized by radiographic evidence of
f o c a li r o na c c u m u l a t i o ni nt h eb r a i n[ 36]. These diseases are
progressive movement disorders caused by nucleotide
i n s e r t i o n si ne x o n4o ft h ef e r r i t i nl i g h tc h a i ng e n e[ 37].
These patients show low levels of serum ferritin [22]a n d
abundant spherical inclusions in the brain, skin, kidney,
liver, and muscle [33] that are positive for iron, ferritin, and
ubiquitin staining [38].
Moreover, abnormal accumulation of iron is also con-
sidered to be involved in the pathogenesis of myelin dis-
eases such as multiple sclerosis (MS). Histochemical studies
have shown that abnormal iron deposits are observed in
reactive microglia, axons, neurons, and oligodendrocytes
in patients with MS [39, 40]. Indeed, ferritin levels are
increasedintheCNSofmicewithexperimentalautoimmune
encephalomyelitis, an animal model of MS [41], and in
the cerebrospinal ﬂuid of MS patients [42, 43]. Since the
synthesis of ferritin can reduce toxic ferrous iron (Fe2+), the
elevated level of ferritin in autoimmune encephalomyelitis
m i c ea n dM Sp a t i e n t si sc o n s i d e r e dt ob ec yt o p r o t e ct i v e[ 40].
Although iron has been demonstrated to have a potential
role in many diseases of the CNS, this paper will focus
mainly on the information regarding the role of iron in AD.
It is well known that transition metals provoke oxidative
stress by generating ROS through the Fenton reaction,
thus causing brain lipid peroxidation [44]a n dp r o t e i n
oxidation [45, 46]. Interestingly, not only has iron been
involved in lipid and protein oxidation but also in DNA
damage. It has been shown that iron is able to oxidize DNA
bases, and it has been suggested that the accumulation of
this transition metal observed in some neurodegenerative
disorders could act by both increasing oxidative genome
damage and also preventing its repair [47]. Iron itself has
been related to neurotoxicity, and its accumulation, mainly
in the hippocampus and cortex, has been observed to occur
before AD lesions are detectable. Moreover, it has been also
demonstrated to accumulate both in AD senile plaques [48]
and in amyloid deposits in AβPP2576 transgenic mouse
modelofAD[49].Interestingly,Aβ insolubleaggregateshave
been shown to be dissolved by metal chelators [50].
Oxidative stress is considered to be the earliest change in
the pathogenesis of AD, and high levels of oxidative stress
have been demonstrated to occur in the clinical precursor
of AD, known as mild cognitive impairment (MCI) [51,
52]. Coincidently, increased iron levels were found both in
the cortex and cerebellum from the preclinical AD/MCI
cases. Moreover, iron concentrations have been found to
be increased in the bilateral hippocampus, parietal cortex,
frontal white matter, putamen, caudate nucleus, thalamus,
rednucleus,substantianigra,anddentatenucleussubregions
of patients with diagnosed AD and in normal elderly
patients [53, 54]. It is important to note that these brain
iron concentrations, particularly those in the parietal cortex
at the early stages of AD, have been found to positively
correlate with the severity of patients’ cognitive impairment
[53]. Although extensive evidence links the dysregulation of
iron homeostasis and AD, relatively little is known about
the resulting forms of iron that accumulate in the brain.
Numerous techniques have been developed in order to
characterize, locate, and quantify iron species and iron-
containing compounds in AD. For example, the use of iron
ﬂuorescence together with synchrotron X-ray absorption
spectroscopy showed in situ iron accumulations containing
high concentrations of ferritin and magnetite in AD brain
tissue sections [55].
Alterations in iron metabolism with age have been
described,andtheymayinvolveironuptakeandrelease,stor-
age, and intracellular metabolism [56–59]. Although some
issuesremain unclear, it is wellknown that thedyshomeosta-
sis of brain iron metabolism is one of the initial events that
trigger neuronal death in some neurodegenerative disorders
[60–63]. Existing evidence shows that these mechanisms
may well be altered by the ageing process with increased
(IA) in the brain as the ﬁnal outcome [64–66]. Age-induced
IA has shown to be a consequence of the accumulation
of diﬀerent iron-containing molecules in diﬀerent brain
regions known to be particularly aﬀected in disorders suchInternational Journal of Alzheimer’s Disease 3
as AD and PD [18, 56]. Cellular studies have shown that
iron is speciﬁcally accumulated in microglia and astrocytes
in the cerebral cortex, cerebellum, substantia nigra, and
hippocampus, and it is believed that this metal ion would be
involved in the neuroinﬂammation observed in AD and PD
[28]. The mechanism underlying IA in the brain is unclear
yet. However, one hypothesis holds that it is the blood brain
barrier dysfunction that is responsible for the exudation of
serum components, with iron among them [67]. Another
hypothesis with strong experimental support proposes that
IA is a consequence of the dysregulation of proteins that
govern metal homeostasis. Among candidates, it has been
demonstrated that the iron regulatory proteins (IREG)
participate in neuronal IA. Increased expression of IREG1
has been related with neuronal survival during IA [68]. In
addition, IREG2 knockout (Ireb2(−/−)) mice develop IA
in white matter tracts and nuclei in diﬀerent brain areas
and display neurodegeneration signs in Purkinje cells [69].
Mutations in the divalent metal transporter 1 (DMT1) have
been shown to impair iron transport and to protect rodents
against neurotoxins like 6-hydroxydopamine, supporting a
critical role for DMT1 in iron-mediated neurodegeneration
[70].MitochondrialIA,lossofiron-sulfurcluster-containing
enzymes,andincreasedoxidativedamageareknowntooccur
in yeast and mouse frataxin-depleted mutants as well as in
tissues and cell lines from Friedrich’s ataxia (FRDA) patients,
suggesting that frataxin may be involved in the export of iron
from the mitochondria, the synthesis of iron-sulfur clusters,
and/ortheprotectionfromoxidativedamage[71].Theuseof
Deferiprone (DFP, a chelator in clinical use for treating iron
overload) in FRDA cells has been found to reduce the mito-
chondrial LIP increased by frataxin deﬁciency [72]. A new
recently reported mitochondrial ferritin (MtFt) speciﬁcally
expressesinhighenergy-consumingcells,includingneurons.
The overexpression of MtFt has been observed to lead to
a cytosolic iron deﬁciency and to signiﬁcantly prevent the
alteration of iron redistribution and, consequently, neuronal
toxicity induced by 6-hydrodopamine [69].
Although the existing data clearly show a relationship
between iron metabolism, aging, and neurodegeneration,
more and deeper studies are needed to completely under-
stand the role of this transition metal in the onset and
progression of neurodegenerative diseases and neurological
age-related disorders.
3. Iron Interaction with
Amyloid Beta (Aβ)P e ptid e
Interestingly, IA, as well as oxidative stress in AD brains,
has been linked to altered Aβ deposition. It is well known
that Aβ accumulates in senile plaques in AD, and it has also
been demonstrated to participate in a positive feedback loop,
where oxidative stress leads to increased Aβ generation, and,
conversely, the mechanism of Aβ polymerization generates
oxidative stress which in turn enhances Aβ production [73].
Additionally, Aβ has been characterized as a metalloprotein
able to bind transition metals (e.g., zinc, iron, copper) via 3
histidine (positions 6, 13, and 14) and 1 tyrosine (position
10) residues located in the hydrophilic N-terminal part of
the peptide [74, 75], and in so doing Aβ would prevent
these potentially redox-active ions from causing oxidative
stress. Notably, the redox potential of iron is signiﬁcantly
attenuated by Aβ, supporting a neuroprotective chelating
role for Aβ in AD pathogenesis [76, 77]. This particular
feature of Aβ could, at least in part, explain the enrichment
of these transition metals in AD plaques [48]. It has been
shownthatnotonlyROSproductioninducesAβ aggregation
but also its ability to bind metal ions as well. Augmented
iron concentrations and oxidative stress have been found to
correlate with changes in the concentration of both soluble
and deposited Aβ [78]. Interestingly, the metal-dependent
generation of ROS by Aβ may be a good target for thera-
peutics.Forexample,chelationtherapywithdesferrioxamine
and clioquinol (which are iron and copper/zinc chelators,
resp.) has shown to induce clinical improvement in patients
with AD [79, 80]. Moreover, coincubation of Aβ from
postmortem AD brains with metal chelators has shown to
dissolve Aβ deposits [81]. In addition, both animal and
humanstudieswithclioquinolhavebeenfoundtoreverseAβ
deposition, improve cognition, general behavior and health,
and lower plasma Aβ levels [79, 82, 83].
Taken together, all these data clearly demonstrate that
a deeper understanding of the metal-related mechanisms
operating in neurodegenerative disorders such as AD is
needed, since it may provide insights into new therapeutic
approaches.
4.Neuronal Signalingduring
Iron-InducedNeurotoxicity
Neurons have developed several mechanisms in response to
oxidative injury; one of them is the activation of signaling
pathways that promote death or survival. The extent and
duration of the oxidative insult as well as the cell type
injured are crucial factors in determining which pathways
are activated, their prevalence, and, in consequence, the ﬁnal
cellular fate [84, 85]. In this aspect, metal-induced oxidative
stress has been implicated as the triggering factor of several
protective and proapoptotic signaling pathways in neurons
[7, 86].
Synapses are sites where the ﬁrst manifestations of neu-
rodegenerative processes are likely to appear. Their vul-
nerability to iron-induced oxidative stress has been largely
demonstrated by the presence of membrane lipid peroxida-
tion, impairment of membrane ion-motive ATPases, glucose
and glutamate transport, and mitochondrial function [87].
In this regard, several key components of signaling pathways
like extracellular signal-regulated kinase (ERK), phospho-
inositide 3-kinase (PI3K), Akt, and glycogen synthase kinase
3β (GSK3β) are activated in situ in isolated synaptic
endings exposed to iron-induced oxidative injury [88, 89].
Moreover, several key biochemical events that are known to
occur in intact neurons undergoing apoptosis (i.e., exposure
of phosphatidylserine on the plasma membrane surface,
activation of caspase-3, mitochondrial calcium uptake, and
ROS accumulation) also occur in isolated synaptosomes4 International Journal of Alzheimer’s Disease
exposed to iron-induced oxidative stress [90]. Synapse loss,
a key event in neurodegenerative disorders, might also
involve in situ apoptotic cascades that might occur before,
or independently of, neuronal death. This assumption is
supported by the appearance of degenerative morphological
changes in synapses preceding amyloid deposition and
neuronal degeneration [91]. However, mechanisms whereby
apoptotic eventstriggeredbyiron-inducedoxidativestressin
synapses propagate to the cell body remain unknown.
Some cellular signaling pathways are clearly linked to
enhanced survival, while others are associated with cell
death. Hence, it has been suggested that the balance between
the magnitude of ERK and Jun kinase (JNK) activation is
key to determining survival. While this idea is still generally
accepted, more recent evidence suggests that ERK can
exert apoptotic inﬂuences, and JNK can exert antiapoptotic
inﬂuences during the cellular response to oxidative stress.
The presence of iron and Aβ provokes a marked decrease
in protein kinase C isoforms, reduced Akt serine/threonine
kinase activity, Bcl-2-associated death promoter (BAD)
phosphorylation, and enhanced p38 mitogen-activated pro-
tein kinase (MAPK) and caspase-9 and caspase-3 activation
[92–94]. In isolated synaptic endings, the coincubation with
iron and Aβ triggers the activation of Akt and ERK signaling
in an oxidation-dependent manner [95]. The phosphoryla-
tion and subsequent inhibition of GSK3β mediated by AMP-
activated protein kinase (AMPK) contributes to protecting
mitochondria against iron-catalyzed oxidative stress [96]. In
AD, abnormal activation of GSK3β pathway might play an
important role in neurodegeneration, and compounds such
as lithium that modulate GSK3β activity have been shown
to reduce Aβ production and tau phosphorylation in APP
transgenic mice [97].
Deferoxamine, a known iron chelator, has been shown
to block all the proapoptotic signaling events triggered by
Aβ-Fe. Moreover, Aβ alone has been shown not to activate
proapoptotic signaling, thus demonstrating that apoptotic
cell death can be only triggered by the presence of iron in
vitro [92–94].
Iron has been found to be required for long-term poten-
tiation in hippocampal CA1 neurons, and it is known to
participateinthestimulationofcalciumreleasethroughROS
produced via the Fenton reaction triggering the stimulation
of the ERK signaling pathway. These results support a
coordinated action between iron and calcium in synaptic
plasticity and raise the possibility that elevated iron levels
may contribute to neuronal degeneration through excessive
intracellular calcium increase caused by iron-induced oxida-
tive stress [98].
As previously mentioned, iron (alone or in combination
with Aβ)i sa b l et oa c t i v a t ed i ﬀerent signaling cascades. The
activation of these signaling pathways is, in most cases,
a necessary upstream event for the activation of several
transcription factors (TFs). These TFs regulate the expres-
sion of speciﬁc genes that participate in cellular events
such as survival or death. Nuclear factor kappa B (NF-
κB) plays crucial roles in cellular resistance to oxidants and
survival. Although the knowledge of NF-κBg e n et a r g e t si n
neurons is limited, it has been demonstrated that this TF can
promote their survival and regulate synaptic plasticity [99].
The involvement of NF-κB in the inhibition of apoptosis
has been well established [100]. NF-κBp l a y sac e n t r a l
role in the induction of neuroprotective antiapoptotic gene
products, such as MnSOD and Bcl-2 that are known to
contribute to ischemic tolerance [101]. Activation of NF-
κB has also been associated with increased resistance of
neurons to apoptosis induced by iron exposure [102]. Levels
of p65 immunoreactivity have been reported to be increased
in neurons and astrocytes associated with Aβ plaques in
the brains of AD patients, suggesting an increased NF-κB
activation [103]. Exposure of cultured neurons to Aβ or
a secreted form of amyloid precursor protein (sAPP) has
shown to induce NF-κB activation, thus suggesting a role
for proteolytic products of APP in NF-κBa c t i v a t i o ni nA D
[104]. Levels of NF-κBa c t i v i t yh a v eb e e nr e p o r t e dt ob e
increased in cholinergic neurons in the basal forebrain of AD
patients [105]. Others have established a correlation between
increased NF-κB activity and COX-2 gene transcription in
brain regions aﬀected in AD patients [106]. In addition,
the inhibition of NF-κB transcriptional activity results in
increased vulnerability of neurons to death induced by Aβ
[107].
Hypoxia-inducible factor (HIF) is a TF that regulates
the expression of more than 60 genes. The expression of
genes relevant to iron metabolism such as ceruloplasmin,
transferrin receptor, transferrin, and heme-oxygenase 1
has been shown to be regulated by HIF [108–111]. Iron
chelation therapy that reduces the size of LIP has been
reported to induce the activity of this TF. Moreover, a new
multifunctional nontoxic, brain permeable iron chelator,
M30,hasshowntoactivatetheHIF-1alphasignalingpathway
in rat primary culture of cortical cells. M30 has also been
found to increase the expression levels of the transcripts
of brain-derived neurotrophic factor (BDNF) and growth-
associated protein-43 (GAP-43). In connection with AD,
M30 has been reported to enhance the levels of phospho-Akt
(Ser473) and phospho-GSK3β (Ser9) and to attenuate Tau
phosphorylation [112].
The activator protein-1 (AP-1) is another redox-sensitive
TF. AP-1 is known to participate in critical cellular processes
such as proliferation, diﬀerentiation, and survival. Strong
evidence supports the involvement of AP-1 in oxidative
stress signaling in neurons. In rat cortical neurons and
astrocytes, H2O2 has been demonstrated to activate MAPK
cascade [113]. Upstream of AP-1, c-Jun-N-terminal kinase
(JNK), and p38 (two stress-related MAPK) has also shown
to be activated by increases in the intracellular levels of
oxidants [114–116]. Both MAPK and AP-1 are implicated
in normal physiological functions of the brain. c-Jun, a
component of AP-1, has been recently attributed a dual role:
it is believed to mediate neurodegeneration and cell death
as well as participate in plasticity and repair mechanisms.
Moreover, upregulation of iron regulatory proteins and
DMT-1 isoforms after neuronal injury induced by kainate
has been foundto be modulated by AP-1 in rat hippocampus
[117].
Activation of JNK signaling in neurons has shown to
increase stress resistance and to extend life span by theInternational Journal of Alzheimer’s Disease 5
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Figure 1:Relationshipbetweentheimpairmentofironmetabolismandneurodegenerativediseases.Impairedironmetabolismisahallmark
in several neurodegenerative diseases such as Parkinson’s (PD) and Alzheimer’s (AD) diseases, multiple sclerosis (MS), amyotrophic lateral
sclerosis (ALS), and neuroferritinopathies. In the case of PD and AD, iron has been shown to play a key role in neuronal fate: depending
on the extent and intensity of the oxidative stress caused by the increase in the labile iron pool, it aﬀects transcriptional activity and
signaling cascades that could participate in neuronal survival or death. Although a role for iron has also been observed in MS, ALS, and
neuroferritinopathies, the molecular events that lead to neuronal death are not fully understood.
activation of the forkhead transcription factor (FOXO)
family in Drosophila [118]. Recent studies have suggested
that MST1 mediates oxidative stress-induced neuronal cell
death by phosphorylating the transcription factor FOXO3
at serine 207, a site that is conserved in other FOXO
family members [119, 120]. All these data support the
hypothesis that FOXO signaling extends life span via
amelioration of oxidative damage and mitochondrial dys-
function in neurons. However, to date, there is no link
between FOXO signaling and iron-induced oxidative stress
in neurons. Understanding signal transduction networks
that participate in iron-induced neurotoxicity constitutes
one essential objective for the discovery of new drugs and
treatments aimed at the improvement and delay of AD
symptoms.
5. Concluding Remarks
In this paper, we summarize the latest knowledge about the
role of iron in neurodegeneration processes. Iron, a redox-
active transition metal, has been proposed as an important
contributing factor to the neuropathology of Alzheimer’s
disease. Even though increasing evidence points towards
iron participation in oxidative stress events and protein
aggregation, we are still far from totally comprehending the
role of this transition metal in the onset and progression
of neurodegenerative disorders (Figure 1). The advancement
in this ﬁeld will be fundamental for the establishment of
new therapies intended for neuronal protection during iron
mismanagement conditions.
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